◼ Archived
Business
🔮 Archynetys predicts: fades by tomorrow — graded ✓ correct
FDA scientists flag concerns with peptides, the trendy molecules RFK Jr. supports
3sources
3articles
1velocity
-80%since first seen
20d agofirst detected
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Coverage (3)
- Peptides are popular and controversial. Why? The Washington Post · 20d ago
- FDA reviewers oppose allowing seven peptides for compounding Endpoints News · 20d ago
- RFK Jr. wants to make it easier to get peptides. FDA scientists disagree. NBC News · 20d ago
Related trends
▲ Peaking
Business
Google launches Gemini 3.6 Flash and 3.5 Flash-Lite, teases Gemini 4
Google has expanded its AI portfolio with three new lightweight Gemini models while teasing the upcoming Gemini 4.
▲ Peaking
Business
Unpacking Anthropic's 100-day sprint into biopharma: Nobel hires, M&A and major ambition
Anthropic is aggressively expanding into biopharma through new AI tools, rare disease research, and strategic talent acquisition.
▲ Peaking
Business
Archer Aviation Stock Soars 20% on New Defense Deal
▲ Peaking
Business
Cracker Barrel sells Maple Street Biscuit Co.
Cracker Barrel is divesting Maple Street Biscuit Co. as part of a series of strategic actions and a sale-leaseback deal.
▲ Peaking
Business
SpaceX sets earnings date, triggering first lock-up expiration for millions of shares
SpaceX is preparing for its first earnings report on August 4, coinciding with a massive $116 billion release of insider shares.
▲ Peaking
Business